Gómez, C.T.; Fernández, F.; Jara, A.; Borda, N.; Moscovicz, F.; Yauri-Huaman, Y.; Caceres-Robles, R.; Pacheco-Otalora, L.F.; Lazarowski, A.; Auzmendi, J.
Subchronic Cannabidiol (CBD) Treatment During the Silent Period Fails to Prevent Increased Seizure Susceptibility Following Lithium-Pilocarpine-Induced Status Epilepticus. Brain Sci. 2026, 16, 851.
https://doi.org/10.3390/brainsci16080851
AMA Style
Gómez CT, Fernández F, Jara A, Borda N, Moscovicz F, Yauri-Huaman Y, Caceres-Robles R, Pacheco-Otalora LF, Lazarowski A, Auzmendi J.
Subchronic Cannabidiol (CBD) Treatment During the Silent Period Fails to Prevent Increased Seizure Susceptibility Following Lithium-Pilocarpine-Induced Status Epilepticus. Brain Sciences. 2026; 16(8):851.
https://doi.org/10.3390/brainsci16080851
Chicago/Turabian Style
Gómez, Claudia Taborda, Florencia Fernández, AgustÃn Jara, Natalia Borda, Franco Moscovicz, Yessenia Yauri-Huaman, Rodrigo Caceres-Robles, Luis F. Pacheco-Otalora, Alberto Lazarowski, and Jerónimo Auzmendi.
2026. "Subchronic Cannabidiol (CBD) Treatment During the Silent Period Fails to Prevent Increased Seizure Susceptibility Following Lithium-Pilocarpine-Induced Status Epilepticus" Brain Sciences 16, no. 8: 851.
https://doi.org/10.3390/brainsci16080851
APA Style
Gómez, C. T., Fernández, F., Jara, A., Borda, N., Moscovicz, F., Yauri-Huaman, Y., Caceres-Robles, R., Pacheco-Otalora, L. F., Lazarowski, A., & Auzmendi, J.
(2026). Subchronic Cannabidiol (CBD) Treatment During the Silent Period Fails to Prevent Increased Seizure Susceptibility Following Lithium-Pilocarpine-Induced Status Epilepticus. Brain Sciences, 16(8), 851.
https://doi.org/10.3390/brainsci16080851
